Analytical Data
-
Gene name
Chrac1
- Application
-
Alternative Names
(CHRAC-1)(DNA polymerase epsilon subunit p15)(NF-YC-like protein)(YC-like protein 1)(YCL1)
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9JKP8
-
Expression Region
2-129aa
-
Molecular Weight
21.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Chrac1, a member of the Chimeric Receptor and Cytokine Superfamily, has garnered significant attention in recent years due to its potential roles in immune regulation and cellular signaling. As a restructured protein, Charc1 plays a crucial role in mediating interactions between immune cells, influencing both innate and adaptive immunity. Research has indicated that this protein may be implicated in various pathological conditions, including autoimmune diseases and cancers, where its expression levels and activity could affect disease progression and response to therapies. The ability to produce recombinant Charc1 protein has enabled scientists to explore its structural properties, functional mechanisms, and potential therapeutic applications in more detail. For instance, studies utilizing recombinant Charc1 are crucial for understanding its ligand interactions and downstream signaling pathways, which can reveal novel targets for drug development. Furthermore, the exploration of Charc1 as a biomarker in clinical settings is an emerging area of interest, potentially aiding in patient stratification and personalized medicine. Given the complexity of immune responses, ongoing research into recombinant Charc1 will continue to contribute to our understanding of its biological significance and therapeutic potential.
